Clinical trials on Prostate cancer

Understanding Prostate Cancer

Prostate cancer is a significant health concern that affects the prostate gland, a small walnut-shaped gland in men responsible for producing seminal fluid. It is one of the most common types of cancer among men, with its likelihood increasing with age. The disease can be slow-growing, confined to the prostate gland initially, making it manageable for many years. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.

Diagnosis and Treatment Options

Early detection of prostate cancer is crucial and can be achieved through screening tests such as Prostate-Specific Antigen (PSA) blood tests or Digital Rectal Exams (DRE). Upon suspicion of cancer, further investigations like biopsies and imaging tests are conducted to confirm the diagnosis. Treatment options for prostate cancer vary depending on the stage and grade of the cancer, as well as the patient’s overall health and preferences. These options may include:

  • Active Surveillance or Watchful Waiting: For low-risk, non-aggressive prostate cancer, monitoring the cancer without immediate treatment might be recommended.
  • Surgery: Radical prostatectomy involves the removal of the prostate gland and some surrounding tissue, a common treatment for localized cancer.
  • Radiation Therapy: This uses high-powered energy to kill cancer cells. It can be delivered externally or internally (brachytherapy).
  • Hormone Therapy: Also known as androgen deprivation therapy (ADT), this treatment aims to reduce the level of male hormones in the body, which can help shrink or slow the growth of cancer cells.

Choosing the right treatment involves careful consideration of the potential benefits and risks, and it is often a decision made in collaboration with a healthcare team. Advances in medical research continue to provide new insights into prostate cancer treatment, offering hope for more effective and less invasive options in the future.

Prostate Cancer Overview

Prostate cancer is a common malignancy that develops in the prostate gland of men. The long-term prognosis for patients with prostate cancer can vary widely based on several factors:

  • Stage at Diagnosis: Early detection often leads to a favorable prognosis with high survival rates.
  • Aggressiveness of Cancer Cells: More aggressive cancer cells can worsen the prognosis.
  • Overall Health of the Patient: Patients in good health tend to have better outcomes.

Localized prostate cancer, confined to the prostate gland, has a particularly good prognosis, with the majority of patients living many years post-diagnosis without the disease significantly impacting their natural lifespan. For more advanced stages, where the cancer has spread beyond the prostate, the prognosis becomes more guarded, and survival rates decrease. However, advancements in medical treatments and monitoring strategies allow many patients with prostate cancer to continue leading active lives. It is important to remember that outcomes can differ on an individual basis, and consulting a healthcare provider is crucial for personalized prognostic information.

Common Complications

Prostate cancer can lead to several health and daily routine complications, including:

  • Urinary Issues: Difficulty with urination, ranging from a weak flow to a complete inability to urinate, causing discomfort and frequent nocturnal bathroom visits.
  • Hematuria: Blood in the urine or semen, which can indicate various conditions, not exclusively cancer.
  • Erectile Dysfunction: Affecting intimate relationships and self-esteem.
  • Bone Pain: Metastasis of the cancer beyond the prostate can lead to pain in the hips, spine, and chest, limiting mobility.
  • Emotional Stress: The impact of prostate cancer and its complications can significantly affect the overall quality of life.

Treatment Methods for Prostate Cancer

In managing prostate cancer, a variety of treatment methods outside of clinical trials are recommended:

  • Dietary Adjustments:
    • Increase intake of fruits, vegetables, and whole grains.
    • Reduce consumption of red meat and processed foods.
  • Physical Activity: Regular exercise, adapted to individual capacity and medical advice, supports overall health.
  • Pharmacotherapy: Medications that modify hormone levels can help control the disease’s growth.
  • Modern Technology:
    • Cryotherapy: Freezing cancer cells.
    • High-Intensity Focused Ultrasound (HIFU): Using focused sound waves to target and destroy cancerous tissue.

Each treatment option should be discussed with a healthcare provider to customize the approach based on the specific condition and preferences of the patient. Personalized treatment plans offer the best chance for effective management of prostate cancer.

  • CT-EU-00034272

    Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Examining the safety of a new potential drug in advanced prostate cancer

    In this clinical trial, the investigational medication ODM-208 is being evaluated for its potential to assist individuals with a challenging form of prostate cancer that doesn’t respond to standard treatments and has spread to other parts of the body. The trial focuses on assessing the safety profile and pharmacokinetics of the medication, aiming to determine the highest tolerated dose.

    • ODM-208- new potential medication for prostate cancer
    • midazolam
  • Study of combination therapy for Prostate Cancer treatment

    This study focuses on testing a new treatment approach for medium-high risk prostate cancer. The therapy, called darolutamide, will be administered with radiation therapy to evaluate its efficacy in destroying cancer cells more effectively. The trial is divided into two ‘arms’: one arm involves patients receiving darolutamide alongside radiation therapy for six months, while the other arm involves patients receiving a different form of therapy (androgen deprivation therapy) along with the same radiation therapy. By comparing the effects of these two treatments, doctors aim to determine which one is more effective against prostate cancer. PSA levels are also used by researchers to assess treatment response in patients.

    • Darolutamide
  • Enhancing treatment for advanced prostate cancer: A study on the efficacy of combining Abemaciclib with standard therapy

    This clinical trial is designed for men who have prostate cancer that has spread to other parts of the body, a condition known as metastatic hormone-sensitive prostate cancer. The primary focus of the study is to investigate the effectiveness of a novel treatment approach by combining abemaciclib with the standard treatment regimen of abiraterone and prednisone.

    The study involves about 900 participants and aims to determine whether this combination therapy can more effectively delay the progression of the disease compared to the standard treatment alone. Researchers will closely monitor the participants’ health, measuring the duration the treatment remains effective and assessing any side effects or improvements in the quality of life of the patients.

    • Abiraterone
    • Abemaciclib
    • Prednisone
    • prednisolone
  • Extended study on enzalutamide’s long-term effects in prostate cancer

    This is a follow-up study for people with prostate cancer that were involved in a previous trial with a drug named enzalutamide. The primary purpose of this study is to obtain long-term safety data of the drug. Participants will continue with the treatment plan they were on in the initial study if it benefits them. Doctor approval is necessary for any changes in treatment dosage. The study entails regular hospital visits every six months, give or take a week. At these visits, doctors will document any adverse effects, additional medications taken, and evaluate if continuation with the treatment is suitable.

    • Prednisone
    • enzalutamide
    • Abiraterone Acetate
  • Study comparing short and long-term radiation therapy with hormone therapy for post-surgery prostate cancer

    This study is about comparing the effects of short-versus long-term hormone therapy with Triptoreline combined with high doses of radiotherapy. Patients who had radical prostatectomy, to avoid relapse, need to take radiotherapy as it is the only therapy option. Previous studies indicated that therapy combining radiotherapy with Triptoreline taken for 6 months is more effective than radiotherapy alone. The goal of this study is to compare 6 versus 24 months of radiotherapy combined with Triptoreline to see if longer therapy is more efficient.

    • Triptoreline
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    • Androgen deprivation therapy
    • Darolutamide
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    • Apalutamide
  • Comparing darolutamide with standard therapy in hormone sensitive prostate cancer

    This study explores a combination therapy using darolutamide and androgen deprivation therapy (ADT) for men with high-risk biochemical recurrence of prostate cancer. ADT are treatments that block androgens production in the body. The trial aims to determine if this combination prolongs the time without cancer worsening or leading to death compared to ADT alone. Participants will be randomly assigned to receive either the combination treatment or a placebo with ADT for 24 months. The study will track cancer progression, overall health, and any side effects, offering potential advancements in prostate cancer treatment.

    • Darolutamide/BAY1841788
  • Apalutamide treatment for advanced prostate cancer post-surgery

    This clinical trial is looking into a treatment that could help people with a high risk of prostate cancer that could spread to other body parts after surgery. The treatment being studied is called apalutamide. The researchers want to see if this apalutamide can help stop the cancer from returning and spreading after surgery, compared to the standard care that these patients get. The trial will measure the amount of time until the cancer comes back, it has spread to other parts, or a patient dies from any cause. If there’s an increase in PSA (it is a protein made by normal cells and prostate cancer cells), the disease might have come back. The trial will also look at whether and how fast the PSA levels increase after recurrence. If there are no such events until the end of the observation period, the patient’s observation will end on the date of their last contact. The trial also looks at how safe this treatment is and what side effects it may cause.

    • Apalutamide
  • Using abemaciclib and darolutamide to fight spreading prostate cancer

    This study is investigating a new combination of two drugs, abemaciclib and darolutamide, to fight advanced prostate cancer that has spread and is not responding after initial treatment. The concept is to determine how safe this combination is and how the patient’s body responds to it. Doctors also want to see how effective these drugs are in controlling cancer. The duration of the study may be up to 32 months. During this period, specialists will carefully monitor possible side effects and the impact of the drugs on the patient’s health. Specialists will try to provide the best possible care to overcome this disease.

    • Darolutamide
    • Abemaciclib
  • Exploring how saruparib and darolutamide affect men with new prostate cancer

    This study is designed to observe the biological effects of two different medications, namely AZD5305 and Darolutamide, on men who have recently been diagnosed with prostate cancer. Men will be randomly given either one of these medications or a combination of both before they undergo a radical prostatectomy, which is a procedure to remove the prostate gland. During the clinical trial, the researchers will closely monitor all participants for any changes related to the medicine, and to see how safe and tolerable the medications are. In addition, the study aims to observe how these treatments affect the planned surgical procedure.

    • Saruparib/AZD5305
    • Darolutamide
  • Evaluating safety and effectiveness of a new drug for advanced cancer

    This is a study to test a new cancer treatment drug called AZD5305. The goal is to find out whether this drug can be used as a standalone treatment or in combination with other cancer treatments. The study aims to test if the drug is safe, whether people can tolerate it, and whether it is effective in reducing cancer in patients with advanced solid tumors. The study will look at any side effects or serious reactions that people might have. The study will also measure how the drug behaves in the body and how much of the drug enters the bloodstream. Participants will be closely monitored throughout the study, with regular check-ups and support from a dedicated medical team.

    • trastuzumab deruxtecan
    • Saruparib
    • camizestrant
    • Dato-DXd
    • Carboplatin
    • Paclitaxel